Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zoledronic Acid
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenacy Announces Launch of Zoledronic Acid Injection, USP in the U.S. Market
Details : Zometa-Generic (zoledronic acid) works by inhibition of bone resorption. It is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma.
Product Name : Zometa-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Zoledronic Acid
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zoledronic Acid
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
DKSH Has Successfully Entered into a Strategic Partnership with SciGen in Vietnam
Details : DKSH has enetered a strategic partnership with SciGen to supply Zometa (zoledronic acid) to the Vietnamese market. it is indicated for the treatment of Advanced cancers.
Product Name : Zometa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 21, 2023
Lead Product(s) : Zoledronic Acid
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership